Poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment

被引:106
作者
Westedt, Ulrich
Kalinowski, Marc
Wittmar, Matthias
Merdan, Thomas
Unger, Florian
Fuchs, Jutta
Schaeller, Susann
Bakowsky, Udo
Kissel, Thomas
机构
[1] Univ Marburg, Dept Pharmaceut & Biopharm, D-35032 Marburg, Germany
[2] Phillips Univ Hosp, Dept Diagnost Radiol, D-35033 Marburg, Germany
关键词
poly(vinylalcohol)-graft-poly(lactide-co-glycolide); nanoparticles; paclitaxel; restenosis;
D O I
10.1016/j.jconrel.2007.01.009
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Catheter-based local delivery of biodegradable nanoparticles (NP) with sustained release characteristics represents a therapeutic approach to reduce restenosis. Paclitaxel-loaded NP consisting of poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) (PVA-g-PLGA) with varying PLGA chain length as well as poly(lactide-co-glycolide) (PLGA), were prepared by a solvent evaporation technique. NP of < 180 nm in diameter characterized by photon correlation spectroscopy (PCs), scanning electron microscopy (SEM), and atomic force microscopy (AFM) are spherical and show smooth surfaces. Yields typically range from 80 to 95% with encapsulation efficiencies between 77 and 87%. The extent of initial in vitro paclitaxel release was affected by the PVA-g-PLGA composition. Blank nanoparticles from PVA(300)-g-PLGA(30) and PVA(300)-g-PLGA(15) showed excellent biocompatibility in rabbit vascular smooth muscle cells (RbVSMC) at polymer concentrations of 0.37 mg/ml. Paclitaxel-loaded NP have an increased antiproliferative effect on cells in comparison to free drug. Confocal laser scanning microscopy of RbVSMC confirmed cellular uptake of nanoparticles composed of fluorescently labeled PVA(300)-g-PLGA(15) loaded with Oregon Green labeled paclitaxel. Cells showed a clearly increased fluorescence activity with a co-localization of paclitaxel and polymer nanoparticles during incubation with particle suspension. To evaluate the antirestenotic effect in vivo, paclitaxel-loaded nanoparticles were administered locally to the wall of balloon-injured rabbit iliac arteries using a porous balloon catheter. As a result a 50% reduction in neointimal area in vessel segments treated with paclitaxel loaded nanoparticles compared to control vessel segments could be observed (local paclitaxel nanoparticle treated segments 0.80 +/- 0.19 mm(2), control segments 1.58 +/- 0.6 mm(2); p < 0.05). (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:41 / 51
页数:11
相关论文
共 55 条
[41]   A mechanistic study of the formation of polymer nanoparticles by the emulsification-diffusion technique [J].
QuintanarGuerrero, D ;
Allemann, E ;
Doelker, E ;
Fessi, H .
COLLOID AND POLYMER SCIENCE, 1997, 275 (07) :640-647
[42]   ANATOMIC BARRIERS INFLUENCE THE DISTRIBUTION OF IN-VIVO GENE-TRANSFER INTO THE ARTERIAL-WALL - MODELING WITH MICROSCOPIC TRACER PARTICLES AND VERIFICATION WITH A RECOMBINANT ADENOVIRAL VECTOR [J].
ROME, JJ ;
SHAYANI, V ;
FLUGELMAN, MY ;
NEWMAN, KD ;
FARB, A ;
VIRMANI, R ;
DICHEK, DA .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (01) :148-161
[43]  
ROPIAK SM, 1999, Patent No. 5860954
[44]   DRUG-THERAPY - PACLITAXEL (TAXOL) [J].
ROWINSKY, EK ;
DONEHOWER, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (15) :1004-1014
[45]   Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: Results with an acute dog model [J].
Song, CX ;
Labhasetwar, V ;
Cui, XM ;
Underwood, T ;
Levy, RJ .
JOURNAL OF CONTROLLED RELEASE, 1998, 54 (02) :201-211
[46]   Biodegradable polymeric nanoparticles as drug delivery devices [J].
Soppimath, KS ;
Aminabhavi, TM ;
Kulkarni, AR ;
Rudzinski, WE .
JOURNAL OF CONTROLLED RELEASE, 2001, 70 (1-2) :1-20
[47]   Sirolimus-eluting stent for the treatment of in-stent restenosis - A quantitative coronary angiography and three-dimensional intravascular ultrasound study [J].
Sousa, JE ;
Costa, MA ;
Abizaid, A ;
Sousa, AGMR ;
Feres, F ;
Mattos, LA ;
Centemero, M ;
Maldonado, G ;
Abizaid, AS ;
Pinto, I ;
Falotico, R ;
Jaeger, J ;
Popma, JJ ;
Serruys, PW .
CIRCULATION, 2003, 107 (01) :24-27
[48]  
Suh HR, 1998, J BIOMED MATER RES, V42, P331, DOI 10.1002/(SICI)1097-4636(199811)42:2<331::AID-JBM19>3.0.CO
[49]  
2-L
[50]  
TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1